News from piramal imaging

Mar 20, 2014, 11:40 ET
http://www.piramal.com/imaging/.  (PRNewsFoto/Piramal Imaging)

FDA Approves Piramal Imaging's Neuraceq™ (florbetaben F18 injection) for PET Imaging of Beta-Amyloid Neuritic Plaques in the Brain

Piramal Imaging today announced that the U.S. Food and Drug Administration (FDA) has approved Neuraceq™. This approval comes only four weeks...

Nov 20, 2013, 09:00 ET
Piramal Life Sciences.  (PRNewsFoto/Piramal Imaging)

Piramal Imaging Enters into a Strategic Partnership and Exclusive Licensing Agreement with Ci-Co Healthcare for Commercialization of Florbetaben F18

Ci-Co Healthcare and Piramal Imaging announce the companies have entered into a strategic partnership and exclusive licensing agreement whereby...

Oct 17, 2013, 09:00 ET
Piramal Life Sciences.  (PRNewsFoto/Piramal Imaging)

Piramal Imaging Highlights New Data for Beta-Amyloid Imaging Agent Florbetaben F18 at EANM 2013

 Piramal Imaging announced today that results from four studies evaluating the Company's PET amyloid imaging agent, florbetaben F18*, will...

Aug 19, 2013, 12:31 ET
Piramal Life Sciences.  (PRNewsFoto/Piramal Imaging)

Piramal Imaging Provides Comments in Response to the Centers for Medicare and Medicaid Services (CMS) Proposed Coverage Decision for Beta-Amyloid Positron Emission Tomography (PET)

 Piramal Imaging announced today that the Company has submitted a detailed response to CMS regarding the draft decision to limit Medicare...

Jul 25, 2013, 10:36 ET

The Centers For Medicare & Medicaid Services (CMS) Draft Decision Could Limit Patient Access To New Technology That May Help In Diagnosing Dementia

 On Wednesday, July 3, 2013, the Centers for Medicare & Medicaid Services (CMS) released its proposed decision memorandum regarding the...

Jul 12, 2013, 10:54 ET
Piramal Life Sciences.  (PRNewsFoto/Piramal Imaging)

Piramal Imaging Highlights New Data for Florbetaben F18 at AAIC 2013

Piramal Imaging announced today that results from five studies evaluating the Company's PET amyloid imaging agent (florbetaben F18*) will be...

Jun 06, 2013, 11:13 ET

Piramal Imaging Highlights New Data for Florbetaben and Other Investigational Radiopharmaceuticals at SNMMI 2013

Piramal Imaging announced today that results from four studies evaluating the Company's PET amyloid imaging agent (florbetaben F18*) will be...

May 07, 2013, 11:45 ET
Piramal Life Sciences.  (PRNewsFoto/Piramal Imaging)

Piramal Imaging Welcomes Ana M. Catafau, M.D., Ph.D., as VP, Clinical Research and Development, Neurosciences

Piramal Imaging SA, a division of Piramal Enterprises, today announced Ana M. Catafau, M.D., Ph.D., has joined the company as vice president (VP)...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge